Pharmacological inhibitors of JNK and ERK kinases SP600125 and U0126 are not appropriate tools for studies of drug metabolism because they activate aryl hydrocarbon receptor

General Physiology and Biophysics

Volumn 27, Issue 2, 2008, Pages 143-146

  Bachleda, Peter ^a   Dvořák, Zdeněk ^b  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Aryl hydrocarbon receptor; ERK; JNK; MAPK; SP600125; U0126

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CELL ISOLATION; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); DRUG METABOLISM; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PROTEIN EXPRESSION; RECEPTOR BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 48749113840     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Andrieux L., Langouet S., Fautrel A., Ezan F., Krauser J. A., Savouret J. F., Guengerich F. P., Baffet G., Guillouzo A. (2004): Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes. Mol. Pharmacol. 65, 934-943
2. Bennett B. L., Sasaki D. T., Murray B. W., O'Leary E. C., Sakata S. T., Xu W., Leisten J. C., Motiwala A., Pierce S., Satoh Y., Bhagwat S. S., Manning A. M., Anderson D. W. (2001): SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A. 98, 13681-13686
3. Bradham C., McClay D. R. (2006): p38 MAPK in development and cancer. Cell Cycle 5, 824-828
4. Chen S., Operana T., Bonzo J., Nguyen N., Tukey R. H. (2005): ERK kinase inhibition stabilizes the aryl hydrocarbon receptor: implications for transcriptional activation and protein degradation. J. Biol. Chem. 280, 4350-4359
5. Cuenda A., Rouse J., Doza Y. N., Meier R., Cohen P., Gallagher T. F., Young P. R., Lee J. C. (1995): SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229-233
6. Dhillon A. S., Hagan S., Rath O., Kolch W. (2007): MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290
7. Dvorak Z., Ulrichova J., Modriansky M. (2005): Role of microtubules network in CYP genes expression. Curr. Drug Metab. 6, 545-552
8. Dvorak Z., Vrzal R., Henklova P., Jancova P., Anzenbacherova E., Maurel P., Svecova L., Pavek P., Ehrmann J., Havlik R., Bednar P., Lemr K., Ulrichova J. (2008): JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A and CYP1A2 genes in primary human hepatocytes. Biochem. Pharmacol. 75, 580-588
9. Favata M. F., Horiuchi K. Y., Manos E, J., Daulerio A. J., Stradley D. A., Feeser W. S., Van Dyk D. E., Pitts W. J., Earl R. A., Hobbs F., Copeland R. A., Magolda R. L., Scherle P. A., Trzaskos J. M. (1998): Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632
10. Henklova P., Vrzal R., Ulrichova J., Dvorak Z. (2008): Role of mitogen-activated protein kinases in aryl hydrocarbon receptor signaling. Chem. Biol. Interact. 172, 93-104
11. Joiakim A., Mathieu P. A., Palermo C., Gasiewicz T. A., Reiners J. J. Jr. (2003): The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metab. Dispos. 31, 1279-1282
12. Kawajiri K., Fujii-Kuriyama Y. (2007): Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. Arch. Biochem. Biophys. 464, 207-212
13. Meloche S., Pouyssegur J. (2007): The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26, 3227-3239
14. Pascussi J. M., Gerbal-Chaloin S., Drocourt L., Assenat E., Larrey D., Pichard-Garcia L., Vilarem M. J., Maurel P. (2004): Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 34, 633-664
15. Pascussi J. M., Gerbal-Chaloin S., Duret C., Daujat-Chavanieu M., Vilarem M. J., Maurel P. (2008): The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Ann. Rev. Pharmacol. Toxicol. 48, 1-32
16. Pavek P., Dvorak Z. (2008): Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab. 9, 129-143
17. Pichard-Garcia L., Gerbal-Chaloin S., Ferrini J. B., Fabre J. M., Maurel P. (2002): Use of long-term cultures of human hepatocytes to study cytochrome P450 gene expression. Methods Enzymol. 357, 311-321
18. Tan Z., Chang X., Puga A., Xia Y. (2002): Activation of mitogen-activated protein kinases (MAPKs) by aromatic hydrocarbons: role in the regulation of aryl hydrocarbon receptor (AHR) function. Biochem. Pharmacol. 64, 771-780
19. Vrzal R., Daujat-Chavanieu M., Pascussi J. M., Ulrichova J., Maurel P., Dvorak Z. (2008): Microtubules-interfering agents restrict aryl hydrocarbon receptor-mediated CYPlA2 induction in primary cultures of human hepatocytes via c-jun-N-terminal kinase and glucocorticoid receptor. Eur. J. Pharmacol. 581, 244-254
20. Weston C. R., Davis R. J. (2007): The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19, 142-149